AVBP
ArriVent BioPharma Inc
$
20.350
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
20.600
Open
19.880
VWAP
20.28
Vol
164.69K
Mkt Cap
840.08M
Low
19.880
Amount
3.34M
EV/EBITDA(TTM)
--
Total Shares
41.28M
EV
539.81M
EV/OCF(TTM)
--
P/S(TTM)
--
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
--
--
-1.033
+14.81%
--
--
-0.937
-50.7%
--
--
-0.755
+23.77%
Estimates Revision
The market is revising No Change the revenue expectations for ArriVent BioPharma, Inc. (AVBP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 1.19%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.28%
In Past 3 Month
Stock Price
Go Up
+1.19%
In Past 3 Month
6 Analyst Rating
Wall Street analysts forecast AVBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVBP is 41.00 USD with a low forecast of 31.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.350
Low
31.00
Averages
41.00
High
47.00
Current: 20.350
Low
31.00
Averages
41.00
High
47.00
Citi
Buy
downgrade
$33 -> $31
2025-11-11
Reason
Citi
Price Target
$33 -> $31
2025-11-11
downgrade
Buy
Reason
Citi lowered the firm's price target on ArriVent Biopharma to $31 from $33 and keeps a Buy rating on the shares.
Clear Street
Kaveri Pohlman
Buy
maintain
$32 -> $47
2025-11-10
Reason
Clear Street
Kaveri Pohlman
Price Target
$32 -> $47
2025-11-10
maintain
Buy
Reason
Clear Street analyst Kaveri Pohlman raised the firm's price target on ArriVent Biopharma to $47 from $32 and keeps a Buy rating on the shares, citing heightened conviction in the success of the first-line Phase 3 Alpacca trial for PACC-mutated NSCLC based on an analysis of historical afatinib and osimertinib outcomes for both ORR and PFS. The firm raised its view of the probability of success to 65% from 30%, the analyst noted.
Citi
Yigal Nochomovitz
Buy
downgrade
$40 -> $33
2025-08-12
Reason
Citi
Yigal Nochomovitz
Price Target
$40 -> $33
2025-08-12
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on ArriVent Biopharma to $33 from $40 and keeps a Buy rating on the shares following the Q2 report. The firm cites the 18% dilution from July's public offering for the target cut but continues to see shared upside into ArriVent's two near-to-medium term data readouts.
H.C. Wainwright
Buy
maintain
$40 -> $42
2025-08-12
Reason
H.C. Wainwright
Price Target
$40 -> $42
2025-08-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on ArriVent Biopharma to $42 from $40 and keeps a Buy rating on the shares. The top-line results from the pivotal Phase 3 FURVENT trial are expected in early 2026, the analyst tells investors in a research note.
Goldman Sachs
Corinne Johnson
initiated
$33
2025-07-10
Reason
Goldman Sachs
Corinne Johnson
Price Target
$33
2025-07-10
initiated
Reason
Goldman Sachs analyst Corinne Johnson resumed coverage of ArriVent Biopharma with a Buy rating and $33 price target. The firm sees a high probability that the Phase3 FURVENT results demonstrate competitive clinical efficacy.
Oppenheimer
Oppenheimer
Outperform
maintain
$39 -> $44
2025-06-24
Reason
Oppenheimer
Oppenheimer
Price Target
$39 -> $44
2025-06-24
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on ArriVent Biopharma to $44 from $39 and keeps an Outperform rating on the shares. ArriVent announced a positive update from firmonertinib's Phase 1b PACC study with 10M longer follow-up, with results meeting the firm's prior best-case scenario, with the 240mg Firmo dose improving confirmed overall response rate to 68.2%, and showing a mean progression free survival of 16M and median duration of response of 14.6M, with a manageable safety profile, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for ArriVent BioPharma Inc (AVBP.O) is -5.44, compared to its 5-year average forward P/E of -6.90. For a more detailed relative valuation and DCF analysis to assess ArriVent BioPharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.90
Current PE
-5.44
Overvalued PE
-5.67
Undervalued PE
-8.12
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.34
Undervalued EV/EBITDA
-6.34
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
YoY :
+58.12%
-38.32M
Operating Profit
FY2025Q3
YoY :
+70.09%
-34.98M
Net Income after Tax
FY2025Q3
YoY :
+36.07%
-0.83
EPS - Diluted
FY2025Q3
-35.80M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
421.3K
Volume
Months
6-9
2
443.0K
Volume
Months
0-12
2
416.1K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AVBP News & Events
Events Timeline
2025-11-10 (ET)
2025-11-10
08:03:30
ArriVent Biopharma announces Q3 earnings per share of 83 cents, surpassing consensus estimate of 78 cents.
2025-09-22 (ET)
2025-09-22
16:20:58
ArriVent Biopharma names Brent Rice as its new chief commercial officer.
2025-09-09 (ET)
2025-09-09
08:08:08
ArriVent Biopharma unveils proof-of-concept findings from Phase 1b FURTHER study
Sign Up For More Events
Sign Up For More Events
News
4.0
09-10TipRanksTop Analysts Recommend 3 Best Stocks to Purchase Now, 9/10/2025
9.0
09-09NewsfilterArrivent Unveils Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Lung Cancer Conference
3.0
08-22NASDAQ.COMExplore the Potential: XBI Could Rise by 55%
Sign Up For More News
People Also Watch
BVS
Bioventus Inc
7.240
USD
+10.87%
TSAT
Telesat Corp
23.760
USD
+0.76%
GLDD
Great Lakes Dredge & Dock Corp
11.860
USD
+1.72%
OSBC
Old Second Bancorp Inc
18.520
USD
+3.18%
GCT
GigaCloud Technology Inc
34.880
USD
+10.26%
IE
Ivanhoe Electric Inc
11.670
USD
-3.95%
LVWR
LiveWire Group Inc
4.020
USD
+6.07%
SCVL
Shoe Carnival Inc
16.640
USD
+5.99%
TYRA
Tyra Biosciences Inc
21.120
USD
+0.57%
FAQ
What is ArriVent BioPharma Inc (AVBP) stock price today?
The current price of AVBP is 20.35 USD — it has increased 1.45 % in the last trading day.
What is ArriVent BioPharma Inc (AVBP)'s business?
What is the price predicton of AVBP Stock?
What is ArriVent BioPharma Inc (AVBP)'s revenue for the last quarter?
What is ArriVent BioPharma Inc (AVBP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ArriVent BioPharma Inc (AVBP)'s fundamentals?
How many employees does ArriVent BioPharma Inc (AVBP). have?